- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02483936
Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control
February 15, 2024 updated by: EMS
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan Medoxomil + Chlorthalidone (40mg + 12.5mg and 40mg + 25mg) Compared With BENICAR HCT® in Hypertension Control
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
Study Overview
Status
Not yet recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
348
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Monalisa F.B. Oliveira, M.D.
- Phone Number: 55
- Email: pesquisa.clinica@ems.com.br
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Signed Consent of the patient;
- Participants with decompensated essential hypertension, classified into stage 1 (with high or very high cardiovascular risk), stage 2 or stage 3 according to the Brazilian Society of Cardiology (2010), who are being treated with monotherapy.
Exclusion Criteria:
- Patients with any clinically significant disease that in the investigator opinion can not participate in the study;
- Secondary hypertension diagnosis or blood pressure above 190x100 mmHg in the screening/randomization visit;
- Morbid obesity or immunocompromised patients;
- Participants with greater than 10 mmHg difference in the measurements of systolic or diastolic blood pressure between the two arms;
- Participants who do not have the two upper limbs;
- Participants with important electrocardiographic changes;
- Creatinine clearance - less than 60 mL / min;
- History of hypertensive emergencies and cardiovascular and / or moderate to severe cerebrovascular events in the past 6 months;
- Microalbuminuria urine sample greater than 30 mg/g;
- Patients with history of hypersensitivity to any of the formula compounds;
- Pregnancy or risk of pregnancy and lactation patients;
- Participation in clinical trial in the year prior to this study;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Test 1: Olmesartan+Chlorthalidone
The patients will take 1 tablet (Olmesartan medoxomil 40 mg + Chlorthalidone 12,5 mg) a day, in the morning.
|
1 tablet a day
|
Experimental: Test 2: Olmesartan+Chlorthalidone
The patients will take 1 tablet (Olmesartan medoxomil 40 mg + Chlorthalidone 25 mg) a day, in the morning.
|
1 tablet a day
|
Active Comparator: Comparator 1: Benicar HCT®
The patients will take 1 tablet (Olmesartan 40mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
|
1 tablet a day
Other Names:
|
Active Comparator: Comparator 2: Benicar HCT®
The patients will take 1 tablet (Olmesartan 40mg + Hydrochlorothiazide 25 mg) a day, in the morning.
|
1 tablet a day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy of essential hypertension control based on the reduction of systolic blood pressure at the end of the study.
Time Frame: 60 days
|
60 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety will be evaluated by the adverse events occurrences
Time Frame: 9 weeks
|
Adverse events will be collected and followed in order to evaluate safety and tolerability
|
9 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
December 1, 2024
Primary Completion (Estimated)
June 1, 2025
Study Completion (Estimated)
September 1, 2026
Study Registration Dates
First Submitted
June 25, 2015
First Submitted That Met QC Criteria
June 25, 2015
First Posted (Estimated)
June 29, 2015
Study Record Updates
Last Update Posted (Actual)
February 16, 2024
Last Update Submitted That Met QC Criteria
February 15, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Sodium Chloride Symporter Inhibitors
- Olmesartan
- Olmesartan Medoxomil
- Hydrochlorothiazide
- Chlorthalidone
Other Study ID Numbers
- OLCEMS0215
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Arterial Hypertension
-
Vanderbilt University Medical CenterJohns Hopkins UniversityCompletedPulmonary Arterial Hypertension | Idiopathic Pulmonary Arterial Hypertension | Associated Pulmonary Arterial Hypertension | Heritable Pulmonary Arterial HypertensionUnited States
-
Klinikum Wels-GrieskirchenEuropean Regional Development Fund; Austrian Society of Hypertension; I.E.M....CompletedSuspected Arterial HypertensionSwitzerland, Austria, Germany, Greece, Italy, Spain, United Kingdom
-
National Institute of Cardiology, Laranjeiras,...CompletedArterial Hypertension | Resistant Arterial HypertensionBrazil
-
Heart Center Leipzig - University HospitalCompletedTherapy Resistant Arterial HypertensionGermany
-
ActelionRecruitingArterial Hypertension, PulmonaryPoland, Germany
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
University of GiessenPhilipps University Marburg Medical CenterRecruitingPulmonary Arterial Hypertension (PAH)Germany
-
Novartis PharmaceuticalsCompletedSevere Pulmonary Arterial HypertensionJapan
-
Zhejiang UniversityUnknownIdiopathic Pulmonary Arterial HypertensionChina
-
Association de Recherche en Physiopathologie RespiratoireGlaxoSmithKline; Soladis; InterlisUnknownPulmonary Arterial Hypertension (PAH)France
Clinical Trials on Olmesartan medoxomil 40mg + chlorthalidone 12,5mg
-
EMSNot yet recruitingEssential Arterial Hypertension
-
TakedaCompletedEssential HypertensionUnited States, Chile, Mexico
-
TakedaCompletedEssential HypertensionUnited States, Canada
-
TakedaCompletedSafetyUkraine, Germany, Poland, Bulgaria, Netherlands, Lithuania, Slovakia, Latvia
-
TakedaCompletedEssential HypertensionNetherlands, Austria, Germany, Poland, United Kingdom
-
Daiichi Sankyo, Inc.CompletedEssential HypertensionFrance, Poland, Ukraine, Belgium, Germany, Spain, Bulgaria, Romania, Denmark, Russian Federation, Netherlands, Austria, Slovakia, Czechia
-
Daiichi Sankyo, Inc.CompletedHypertensionUnited States, Colombia, Argentina, Peru, Brazil, Kenya, Chile, South Africa, India, Zambia, Uganda
-
Lee's Pharmaceutical LimitedCompleted
-
Jiangsu HengRui Medicine Co., Ltd.Unknown
-
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyTerminatedChronic Heart Failure | High Blood B-type (or Brain) Natriuretic Peptide (BNP) LevelGermany, France, Netherlands